LB Pharmaceuticals to Participate in Upcoming Investor Events
Key Highlights
- ➤LB Pharmaceuticals will present at four healthcare investor conferences in October and November 2026
- ➤LB-102 could become the first benzamide antipsychotic approved for neuropsychiatric disorders in the United States
- ➤Fireside chats and investor meetings are scheduled in Boston, New York, and virtually
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:
Craig-Hallum Biotech Catalyst Conference * Virtual fireside chat at 10:00 a.m. ET and virtual 1x1 investor meetings on Thursday, October 22, 2026 Guggenheim Securities 3(rd) Annual Healthcare Innovation Conference * Fireside chat at 1:00 p.m. ET and 1x1 investor meetings on Monday, November 9, 2026, in Boston, MA Wolfe Research Healthcare Conference * 1x1 investor meetings on Tuesday, November 10, 2026, in New York, NY Stifel Healthcare Conference * Fireside chat at 9:20 a.m. ET and 1x1 investor meetings on Thursday, November 12, 2026, in New York, NY Webcasts for the fireside chats will be available on the “Investors” section under the “Events” page of the Company’s website at https://ir.lbpharma.us/, where a replay of the webcasts will be archived.
Get started
Create a free account to read the full story.